专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

US07081458B2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues 失效
标题翻译：黑色素浓缩激素受体配体：取代的1-苄基-4-芳基哌嗪类似物
公开(公告)号：US07081458B2
公开(公告)日：2006-07-25
申请号：US11103246
申请日：2005-04-11
申请人： Alan J. Hutchison , John M. Peterson , Dario Doller , Wallace C. Pringle , Helen Yin
发明人： Alan J. Hutchison , John M. Peterson , Dario Doller , Wallace C. Pringle , Helen Yin
IPC分类号： A61K31/407 , A61K31/4439 , C07D487/04
CPC分类号： C07D513/04 , C07D209/86 , C07D211/52 , C07D213/64 , C07D213/74 , C07D215/12 , C07D215/20 , C07D243/08 , C07D295/096 , C07D295/108 , C07D311/18 , C07D317/58 , C07D401/12 , C07D471/04 , C07D487/04 , C07D487/08
摘要： Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
摘要翻译：提供能够调节MCH受体活性的黑色素浓缩激素受体配体（特别是1-苄基-4-芳基哌嗪，1-苄基-4-芳基哌啶和相关化合物）。这样的配体可用于在体内或体外调节MCH与MCH受体的结合，并且特别可用于治疗人，驯养的伴侣动物和家畜中的各种代谢，喂养和性障碍。还提供了用于治疗这种病症的药物组合物和方法，以及使用这些配体检测MCH受体的方法（例如受体定位研究）。

92. 发明授权

US07015349B2 Reduction of hair growth 失效
标题翻译：减少头发生长
公开(公告)号：US07015349B2
公开(公告)日：2006-03-21
申请号：US10397132
申请日：2003-03-26
申请人： Anwar Jardien , Roman Rariy , Gurpreet S. Ahluwalia , Douglas Shander
发明人： Anwar Jardien , Roman Rariy , Gurpreet S. Ahluwalia , Douglas Shander
IPC分类号： C07C229/00 , C07C53/15 , C07C239/00 , C07C33/24
CPC分类号： C07D307/52 , A61K8/44 , A61K8/69 , A61Q7/02 , C07C251/20 , C07D213/68 , C07D311/36 , C07D317/58
摘要： Compositions including a conjugate of α-difluoromethylornithine can be applied topically to reduce hair growth.
摘要翻译：可以局部施用包括α-二氟甲基鸟氨酸缀合物的组合物以减少毛发生长。

93. 发明申请

US20060057481A1 Hydrazone compound, electrophotographic photoreceptor comprising the hydrazone compound, and image forming apparatus equipped with the electrophotographic photoreceptor 有权
标题翻译：腙化合物，包含腙化合物的电子照相感光体和配有电子照相感光体的图像形成装置
公开(公告)号：US20060057481A1
公开(公告)日：2006-03-16
申请号：US11220401
申请日：2005-09-07
申请人： Akihiro Kondoh , Takatsugu Obata
发明人： Akihiro Kondoh , Takatsugu Obata
IPC分类号： G03G5/05 , C07D213/42 , C07C251/86
CPC分类号： C07D231/12 , C07C251/86 , C07D277/64 , C07D307/52 , C07D307/81 , C07D311/58 , C07D317/58 , C07D405/12 , G03G5/0616 , G03G5/0672
摘要： A hydrazone compound capable of realizing an electrophotographic photoreceptor having good electric properties such as good sensitivity and light responsibility, good electric and mechanical durability and good environment stability, is provided. The hydrazone compound is represented by the following general formula (1). The compound is contained in the charge transporting layer of the electrophotographic photoreceptor.
摘要翻译：提供能够实现具有良好的灵敏度和轻负荷，良好的电气和机械耐久性以及良好的环境稳定性等良好电性的电子照相感光体的腙化合物。腙化合物由以下通式（1）表示。化合物包含在电子照相感光体的电荷输送层中。

94. 发明申请

US20060041014A1 Treatment of male sexual dysfunction 审中-公开
公开(公告)号：US20060041014A1
公开(公告)日：2006-02-23
申请号：US11170397
申请日：2005-06-28
申请人： Alasdair Naylor , Pieter Van Der Graaf , Christopher Wayman
发明人： Alasdair Naylor , Pieter Van Der Graaf , Christopher Wayman
IPC分类号： A61K31/195
CPC分类号： A61K45/06 , A61K31/00 , A61K31/165 , A61K31/17 , A61K31/18 , A61K31/19 , A61K31/196 , A61K31/395 , A61K31/4015 , A61K31/433 , A61K31/4412 , A61K31/454 , C07C233/58 , C07C233/60 , C07C235/40 , C07C237/22 , C07C237/24 , C07C275/52 , C07C311/13 , C07C311/18 , C07C311/51 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D207/14 , C07D207/27 , C07D209/14 , C07D211/40 , C07D213/64 , C07D213/70 , C07D213/75 , C07D285/12 , C07D285/135 , C07D307/81 , C07D317/58 , G01N2800/344 , A61K2300/00
摘要： The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

95. 发明授权

US06991911B2 Assay for entactogens 有权
标题翻译：检测细菌
公开(公告)号：US06991911B2
公开(公告)日：2006-01-31
申请号：US10736005
申请日：2003-12-15
申请人： Yi Feng Zheng , Hshiou-ting Liu
发明人： Yi Feng Zheng , Hshiou-ting Liu
IPC分类号： G01N33/53 , G01N33/531 , C07K16/00 , C07K17/02 , C07D317/58
CPC分类号： C07D405/12 , C07D317/58 , C07K16/44 , G01N33/946 , Y10S435/961 , Y10S435/975
摘要： Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.
摘要翻译：公开了方法，组合物和试剂盒。该方法涉及确定活性成分分析物的存在，例如3,4-亚甲二氧基苯丙胺（MDA），3,4-亚甲二氧基 - 甲基苯丙胺（MDMA），3,4-亚甲二氧基 - 乙基苯丙胺（MDEA）和4- 羟基-3-甲氧基 - 甲基苯丙胺（HMMA）。该方法包括在介质中提供（i）怀疑含有该化合物的样品和（ii）针对包含蛋白质的式I化合物产生的抗体。检查介质是否存在包含化合物和抗体的复合物，其中诸如复合物的存在表明样品中存在化合物。在上述实施方案的一个方面，组合还包含化合物式I的标记缀合物。

96. 发明申请

US20050282908A1 Substituted aminopropoxyaryl derivatives useful as agonists for LXR 审中-公开
标题翻译：可用作LXR激动剂的取代的氨基丙氧基芳基衍生物
公开(公告)号：US20050282908A1
公开(公告)日：2005-12-22
申请号：US11154852
申请日：2005-06-16
申请人： Jon Collins , Adam Fivush , Patrick Maloney , Eugene Stewart , Timothy Willson
发明人： Jon Collins , Adam Fivush , Patrick Maloney , Eugene Stewart , Timothy Willson
IPC分类号： C07D233/64 , A61K31/165 , A61K31/192 , A61K31/216 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4045 , A61K31/415 , A61K31/417 , A61K31/4184 , A61K31/42 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4468 , A61K31/513 , A61K45/00 , A61P3/06 , A61P9/00 , A61P9/10 , A61P43/00 , C07C217/22 , C07C217/58 , C07C235/34 , C07C235/46 , C07C255/58 , C07C317/32 , C07C323/32 , C07D207/09 , C07D209/14 , C07D211/58 , C07D213/36 , C07D213/38 , C07D213/74 , C07D213/78 , C07D213/82 , C07D231/16 , C07D233/54 , C07D235/10 , C07D235/14 , C07D235/16 , C07D235/26 , C07D239/52 , C07D261/08 , C07D277/28 , C07D307/52 , C07D307/79 , C07D307/81 , C07D309/20 , C07D317/58 , C07D317/62 , C07D317/64 , C07D319/18 , C07D333/20 , C07C233/62
CPC分类号： C07D213/82 , C07C217/22 , C07C217/58 , C07C235/34 , C07C235/46 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/42 , C07D207/09 , C07D209/14 , C07D211/58 , C07D213/38 , C07D231/16 , C07D233/64 , C07D235/14 , C07D235/16 , C07D239/52 , C07D261/08 , C07D277/28 , C07D307/52 , C07D307/79 , C07D307/81 , C07D309/20 , C07D317/58 , C07D317/62 , C07D317/64 , C07D319/18 , C07D333/20
摘要： The invention relates to a compound of formula (I), wherein all variables are as defined herein, and pharmaceutically acceptable salts or solvates thereof. The compounds of formula (I) are useful as LXR agonists.
摘要翻译：本发明涉及式（I）化合物，其中所有变量如本文所定义，及其药学上可接受的盐或溶剂化物。式（I）化合物可用作LXR激动剂。

98. 发明申请

US20050192283A1 Fused-aryl and heteroaryl derivatives and methods of their use 失效
标题翻译：稠合芳基和杂芳基衍生物及其使用方法
公开(公告)号：US20050192283A1
公开(公告)日：2005-09-01
申请号：US10963064
申请日：2004-10-12
申请人： Eugene Trybulski , Paige Mahaney , Lori Gavrin , Joseph Sabatucci , Gary Stack
发明人： Eugene Trybulski , Paige Mahaney , Lori Gavrin , Joseph Sabatucci , Gary Stack
IPC分类号： A61K31/496 , C07D207/14 , C07D207/22 , C07D209/14 , C07D211/48 , C07D211/56 , C07D211/58 , C07D213/36 , C07D213/38 , C07D215/12 , C07D215/14 , C07D295/084 , C07D307/34 , C07D307/52 , C07D307/81 , C07D309/04 , C07D309/10 , C07D317/58 , C07D333/20 , C07D333/28 , C07D333/58 , C07D333/66 , C07D409/06 , C07D413/02 , C07D43/02 , C07D49/02
CPC分类号： C07D295/092 , A61K31/496 , C07D207/14 , C07D207/22 , C07D209/14 , C07D211/48 , C07D211/56 , C07D211/58 , C07D213/38 , C07D215/12 , C07D307/34 , C07D307/52 , C07D307/81 , C07D309/10 , C07D317/58 , C07D333/28 , C07D333/58 , C07D409/06
摘要： The present invention is directed to fused-aryl and heteroaryl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
摘要翻译：本发明涉及稠合芳基和杂芳基衍生物，含有这些衍生物的组合物及其用于预防和治疗由单胺再摄取改善的病症的方法，其中尤其包括血管舒缩症状（VMS），性功能障碍，胃肠道和特别是选自重症抑郁障碍，血管舒缩症状，压力和急迫性尿失禁，纤维肌痛，疼痛，糖尿病性神经病变及其组合的那些病症，特别是选自下列的那些病症：泌尿生殖系统疾病，慢性疲劳综合征，纤维瘤病综合征，神经系统疾病及其组合。

99. 发明授权

US06924263B2 Oxime methyl ethers 失效
标题翻译：肟甲基醚
公开(公告)号：US06924263B2
公开(公告)日：2005-08-02
申请号：US10232200
申请日：2002-08-29
申请人： Anubhav P. S. Narula , Rajamony Mahesh , Manfred Pawlak , Clint Dee Winton Brooks
发明人： Anubhav P. S. Narula , Rajamony Mahesh , Manfred Pawlak , Clint Dee Winton Brooks
IPC分类号： C07D317/58 , C11B9/00 , A61K7/46
CPC分类号： C11B9/0069 , C07D317/58
摘要： The use of various oxime ethers are described as fragrance chemicals, suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed. Novel compounds are also disclosed.
摘要翻译：各种肟醚的使用被描述为适用于制造香料的芳香化学品，并且公开了香料，古龙水和个人护理产品中的香料。还公开了新的化合物。

100. 发明授权

US06916956B2 Calcium receptor antagonist 失效
标题翻译：钙受体拮抗剂
公开(公告)号：US06916956B2
公开(公告)日：2005-07-12
申请号：US10344157
申请日：2001-08-10
申请人： Yuko Shinagawa , Takeo Katsushima , Takashi Nakagawa
发明人： Yuko Shinagawa , Takeo Katsushima , Takashi Nakagawa
IPC分类号： C07C217/28 , C07C217/60 , C07C217/76 , C07C229/38 , C07C233/25 , C07C235/42 , C07C235/60 , C07C237/30 , C07C255/54 , C07C311/21 , C07C311/29 , C07D213/30 , C07D277/24 , C07D307/42 , C07D317/58 , C07D333/16 , C07D333/56 , C07C217/10 , C07D33/16
CPC分类号： C07D213/30 , C07B2200/07 , C07C217/28 , C07C217/60 , C07C217/76 , C07C229/38 , C07C233/25 , C07C235/42 , C07C235/60 , C07C237/30 , C07C255/54 , C07C311/21 , C07C311/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D277/24 , C07D307/42 , C07D317/58 , C07D333/16 , C07D333/56
摘要： A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.
摘要翻译：其中R 1为式（I）的化合物为任选取代的芳基或任选取代的杂芳基; R 2是任选取代的C 1-6烷基，C 3-7环烷基等; R 3是氢原子，C 1-6烷基，羟基等; R 4是氢原子，C 1-6烷基等; R 5和R 6各自为C 1-6烷基等; R 7是任选取代的芳基或任选取代的杂芳基; X 1，X 2和X 3各自为C 1-6亚烷基等; 和X 4和X 5各自为单键，亚甲基等，其盐，其溶剂合物或其前药，以及含有化合物，特别是钙受体拮抗剂和骨质疏松症的治疗剂。本发明的化合物可用作伴有异常钙稳态或骨质疏松症，hypoparathyreosis，骨肉瘤，牙周病，骨折，骨关节炎，慢性类风湿性关节炎，佩吉特氏病，体液性高钙血症，常染色体显性低钙血症的疾病的治疗药物喜欢。此外，还提供了化合物的中间体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式